Remove tag impact-analysis
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. However, they cannot provide a cure and have a very limited impact on halting disease progression. DMTs for MS have a high price tag, particularly in the US.

Marketing 246
article thumbnail

Grand Rounds March 10, 2023: Estimands in Cluster-Randomized Trials: Choosing Analyses that Answer the Right Question (Brennan Kahan, PhD)

Rethinking Clinical Trials

A cluster-average treatment effect better enables the evaluation of an intervention or treatment’s impact directly on clusters. Mixed-effects models or Generalized Estimating Equations (GEE) are the most common analysis methods for clustered randomized trials, but when informative cluster size is present, both are bias.

Trials 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Google’s 2021 Title Shakeup Part 2: Our SERP Title Analysis Study

Intouch Solutions

blue links) of the organic results appeared to be pulling from content outside of the HTML title tag at a much higher frequency. With that, the Intouch SEO team has assessed the impact of these changes across our pharma clients’ brands. Specifically, title links (i.e., Screaming Frog, Ahrefs, GSC, etc.). Considerations.

article thumbnail

Google’s 2021 Title Shakeup Part 1: What Pharma Marketers Should Know

Intouch Solutions

blue links) of the organic results appeared to be pulling from content outside of the HTML title tag at a much higher frequency. With that, the Intouch SEO team has assessed the impact of these changes across our pharma clients’ brands. Title Tag – This is an HTML element that provides a title for the page. Source: Google.

article thumbnail

Grand Rounds October 6, 2023: Hybrid Studies Should Not Sacrifice Rigorous Methods (David M. Murray, PhD; Moderator: Jonathan Moyer, PhD)

Rethinking Clinical Trials

The group considered the project aims, study design, statistical analysis plan, and power analysis for each center until all aspects were aligned. Throughout the time the Technical Assistance Workgroup worked with the 7 Clinical Centers, they learned that implementation research has its own practices in many design and analysis areas.

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications. During 2001–10, the number of granted designations almost tripled, with 1,527 drugs receiving their first orphan drug designation.

Drugs 246
article thumbnail

Grand Rounds December 16, 2022: The Use of EHR-Agnostic Clinical Decision Support to Prevent Thromboembolism in Hospitalized Medically Ill Patients (Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC; Jeffrey Solomon, BFA)

Rethinking Clinical Trials

The solution’s interface was developed using workflow analysis, multiple iterations of the tool and usability testing. The tool’s success is attributed to workflow analysis, rapid prototyping, usability testing and its integration with the EHR. In doing this, they were able to replicate the data among different populations.